Shares of Insmed Inc. (Nasdaq: INSM) hiked 15% to a close of 46 cents yesterday, spurred by word the biopharmaceutical company has demonstrated the bioequivalence of INS-19, the company’s recombinant human granulocyte colony stimulating factor (G-CSF). The company compared G-CSF to FDA-approved Neupogen, used to treat neutropenia, a disorder characterized by an abnormally low number of white blood cells.